Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products

References

• Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998;15:11–22
   PubMed Web of Science ®Google Scholar
• Grass GM. Simulation models to predict oral drug absorption from in vitro data. Adv Drug Deliv Rev 1997;23:199–219
   Web of Science ®Google Scholar
• Patel N, Forbes B, Murray J. Use of simulated intetsinal fluids with Caco-2 cells and rat ileum. Drug Dev Ind Pharm 2006;32:151–61
   PubMed Web of Science ®Google Scholar
• Tandt LAGL, Stubbs C, Kanfer I. Level a in vitro/in vivo correlations: a quality control tool or bioequivalence predictor for extended-release solid oral dosage forms? Drug Dev Ind Pharm 1995;21:889–904
   Web of Science ®Google Scholar
• Shono Y, Jantratid E, Dressman JB. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. Eur J Pharm Biopharm 2011;79:349–56
   PubMed Web of Science ®Google Scholar
• Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 1983;72:1103–27
   PubMed Web of Science ®Google Scholar
• Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007;3:235–49
   PubMed Web of Science ®Google Scholar
• Poulin P, Jones RD, Jones HM, et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci 2011;100:4127–57
   PubMed Web of Science ®Google Scholar
• Parrott N, Paquereau N, Coassolo P, et al. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 2005;94:2327–43
   PubMed Web of Science ®Google Scholar
• Parrott N, Davies B, Hoffmann G, et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet 2011;50:613–23
   PubMed Web of Science ®Google Scholar
• Rowland M, Balant L, Peck C, et al. Physiologically based pharmacokinetics in Drug Development and Regulatory Science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002). AAPS J 2004;6:56–67
   PubMedGoogle Scholar
• Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011;89:259–67
   PubMed Web of Science ®Google Scholar
• Kostewicz ES, Aarons L, Bergstrand M, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci 2013;57:300–21
   PubMed Web of Science ®Google Scholar
• Otsuka K, Shono Y, Dressman J. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms. J Pharm Pharmacol 2013;65:937–52
   PubMed Web of Science ®Google Scholar
• Shono Y, Jantratid E, Kesisoglou F, et al. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm 2010;76:95–104
   PubMed Web of Science ®Google Scholar
• Shono Y, Jantratid E, Janssen N, et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm 2009;73:107–14
   PubMed Web of Science ®Google Scholar
• Garbacz G, Klein S. Dissolution testing of oral modified-release dosage forms. J Pharm Pharmacol 2012;64:944–68
   PubMed Web of Science ®Google Scholar
• Fotaki N, Vertzoni M. Biorelevant dissolution methods and their applications in in vitro–in vivo correlations for oral formulations. Open Drug Deliv J 2010;4:2–13
   Google Scholar
• Bioequivalence study comparing linezolid 600 mg oral suspension with 600 mg tablet in Chinese healthy male subjects. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01055769?term=Linezolid&rank=6 [last accessed 30 April 2014]
   Google Scholar
• International application published under Patent Co-operation Treaty (PCT), Patent no. WO 2008/145/143 A1, Once daily oral dosage form comprising tacrolimus, Applicant: LifeCycle Pharma A/S, Denmark
   Google Scholar
• Clinical pharmacology and biopharmaceutics review of Valganciclovir tablets (450 mg); Clinical Pharmacology and biopharmaceutics review: Centre for Drug Evaluation and Research; Application no. 21-304; Roche Global Development; 2004
   Google Scholar
• Clinical pharmacology and biopharmaceutics review of Mesalamine controlled release capsules (500 mg); Clinical Pharmacology and biopharmaceutics review: Centre for Drug Evaluation and Research; Application no. 020049; Shire Pharmaceuticals, UK; 1993
   Google Scholar
• Stalker DJ, Jungbluth GL, Hopkins NK, et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrobial Chemother 2003;51:1239–46
   PubMed Web of Science ®Google Scholar
• Moller A, Iwasaki K, Kawamura A, et al. The disposition of 14C-Labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 1998;27:633–6
   Web of Science ®Google Scholar
• Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987;28:196–200
   PubMed Web of Science ®Google Scholar
• Fei Y, Kostewicz ES, Sheu MT, et al. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. Eur J Pharm Biopharm 2013;85:1274–84
   PubMed Web of Science ®Google Scholar
• Nicolaides E, Symillides M, Dressman JB, et al. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 2001;18:380–8
   PubMed Web of Science ®Google Scholar